FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096261775> ?p ?o ?g. }

• W2096261775 endingPage "4115" @default.
• W2096261775 startingPage "4112" @default.
• W2096261775 abstract "ABSTRACT Carbapenemase-producing Klebsiella pneumoniae (KPC) bacteria are rapidly becoming one of the most detrimental drug-resistant Gram-negative pathogens. Doripenem is the newest FDA-approved carbapenem that has the greatest in vitro potency against a wide range of Gram-negative organisms, including multidrug-resistant organisms. Previous work in an animal model has shown efficacy against Pseudomonas aeruginosa with MICs above the current breakpoints of susceptibility. The purpose of this study is to evaluate the efficacy of 1-g and 2-g dose prolonged infusions of doripenem against KPC isolates in both an immunocompetent and neutropenic murine thigh model. Seven clinical KPC isolates (broth microdilution [BMD] MIC range, 4 to 32 μg/ml; Etest MIC range, 3 to >32 μg/ml) were used. After infection, groups of mice were administered doripenem doses previously shown to simulate the exposures observed in humans after the administration of 1 or 2 g every 8 h as a 4-h infusion. In immunocompromised mice, 1- and 2-g doses of doripenem achieved bacteriostasis against isolates with MICs up to and including 8 μg/ml and 16 μg/ml, respectively. In immunocompetent animals, statistically significant reductions in the number of CFU were observed with overall decreases of approximately 1 log ( P < 0.05). While carbapenemase-producing Klebsiella pneumoniae continues to decrease our meager supply of active agents, the ability of doripenem to produce CFU reductions in the presence of white blood cells (WBCs) using humanized exposures suggests the potential utility of this agent in combination against this increasingly problematic pathogen." @default.
• W2096261775 created "2016-06-24" @default.
• W2096261775 creator A5019354236 @default.
• W2096261775 creator A5090740872 @default.
• W2096261775 date "2010-10-01" @default.
• W2096261775 modified "2023-09-27" @default.
• W2096261775 title "<i>In Vivo</i> Efficacy of Simulated Human Dosing Regimens of Prolonged-Infusion Doripenem against Carbapenemase- Producing <i>Klebsiella pneumoniae</i>" @default.
• W2096261775 cites W1750446959 @default.
• W2096261775 cites W1902535075 @default.
• W2096261775 cites W1983273195 @default.
• W2096261775 cites W1993045657 @default.
• W2096261775 cites W2065360334 @default.
• W2096261775 cites W2088168208 @default.
• W2096261775 cites W2103703198 @default.
• W2096261775 cites W2113319277 @default.
• W2096261775 cites W2120444754 @default.
• W2096261775 cites W2128286530 @default.
• W2096261775 cites W2144126572 @default.
• W2096261775 cites W2149923935 @default.
• W2096261775 doi "https://doi.org/10.1128/aac.00026-10" @default.
• W2096261775 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2944615" @default.
• W2096261775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20660688" @default.
• W2096261775 hasPublicationYear "2010" @default.
• W2096261775 type Work @default.
• W2096261775 sameAs 2096261775 @default.
• W2096261775 citedByCount "50" @default.
• W2096261775 countsByYear W20962617752012 @default.
• W2096261775 countsByYear W20962617752013 @default.
• W2096261775 countsByYear W20962617752014 @default.
• W2096261775 countsByYear W20962617752015 @default.
• W2096261775 countsByYear W20962617752016 @default.
• W2096261775 countsByYear W20962617752017 @default.
• W2096261775 countsByYear W20962617752018 @default.
• W2096261775 countsByYear W20962617752019 @default.
• W2096261775 countsByYear W20962617752020 @default.
• W2096261775 countsByYear W20962617752022 @default.
• W2096261775 crossrefType "journal-article" @default.
• W2096261775 hasAuthorship W2096261775A5019354236 @default.
• W2096261775 hasAuthorship W2096261775A5090740872 @default.
• W2096261775 hasBestOaLocation W20962617751 @default.
• W2096261775 hasConcept C104317684 @default.
• W2096261775 hasConcept C150903083 @default.
• W2096261775 hasConcept C176947019 @default.
• W2096261775 hasConcept C207001950 @default.
• W2096261775 hasConcept C2776685102 @default.
• W2096261775 hasConcept C2777058267 @default.
• W2096261775 hasConcept C2777637488 @default.
• W2096261775 hasConcept C2777821550 @default.
• W2096261775 hasConcept C2779375183 @default.
• W2096261775 hasConcept C2780950330 @default.
• W2096261775 hasConcept C501593827 @default.
• W2096261775 hasConcept C523546767 @default.
• W2096261775 hasConcept C54355233 @default.
• W2096261775 hasConcept C547475151 @default.
• W2096261775 hasConcept C55493867 @default.
• W2096261775 hasConcept C71924100 @default.
• W2096261775 hasConcept C81396022 @default.
• W2096261775 hasConcept C86803240 @default.
• W2096261775 hasConcept C89423630 @default.
• W2096261775 hasConcept C94665300 @default.
• W2096261775 hasConcept C98274493 @default.
• W2096261775 hasConceptScore W2096261775C104317684 @default.
• W2096261775 hasConceptScore W2096261775C150903083 @default.
• W2096261775 hasConceptScore W2096261775C176947019 @default.
• W2096261775 hasConceptScore W2096261775C207001950 @default.
• W2096261775 hasConceptScore W2096261775C2776685102 @default.
• W2096261775 hasConceptScore W2096261775C2777058267 @default.
• W2096261775 hasConceptScore W2096261775C2777637488 @default.
• W2096261775 hasConceptScore W2096261775C2777821550 @default.
• W2096261775 hasConceptScore W2096261775C2779375183 @default.
• W2096261775 hasConceptScore W2096261775C2780950330 @default.
• W2096261775 hasConceptScore W2096261775C501593827 @default.
• W2096261775 hasConceptScore W2096261775C523546767 @default.
• W2096261775 hasConceptScore W2096261775C54355233 @default.
• W2096261775 hasConceptScore W2096261775C547475151 @default.
• W2096261775 hasConceptScore W2096261775C55493867 @default.
• W2096261775 hasConceptScore W2096261775C71924100 @default.
• W2096261775 hasConceptScore W2096261775C81396022 @default.
• W2096261775 hasConceptScore W2096261775C86803240 @default.
• W2096261775 hasConceptScore W2096261775C89423630 @default.
• W2096261775 hasConceptScore W2096261775C94665300 @default.
• W2096261775 hasConceptScore W2096261775C98274493 @default.
• W2096261775 hasIssue "10" @default.
• W2096261775 hasLocation W20962617751 @default.
• W2096261775 hasLocation W20962617752 @default.
• W2096261775 hasLocation W20962617753 @default.
• W2096261775 hasLocation W20962617754 @default.
• W2096261775 hasOpenAccess W2096261775 @default.
• W2096261775 hasPrimaryLocation W20962617751 @default.
• W2096261775 hasRelatedWork W2055011594 @default.
• W2096261775 hasRelatedWork W2055786907 @default.
• W2096261775 hasRelatedWork W2096261775 @default.
• W2096261775 hasRelatedWork W2096363361 @default.
• W2096261775 hasRelatedWork W2105640536 @default.
• W2096261775 hasRelatedWork W2130126087 @default.
• W2096261775 hasRelatedWork W2151828834 @default.
• W2096261775 hasRelatedWork W2169439341 @default.
• W2096261775 hasRelatedWork W2790937404 @default.

• next